Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/07/23
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023GlobeNewsWire • 10/31/23
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)GlobeNewsWire • 10/26/23
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023GlobeNewsWire • 10/25/23
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of DiabetesGlobeNewsWire • 09/26/23
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or OverweightGlobeNewsWire • 09/12/23
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/10/23
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023GlobeNewsWire • 08/03/23
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)GlobeNewsWire • 08/01/23
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023GlobeNewsWire • 06/16/23
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023GlobeNewsWire • 06/15/23
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/11/23
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023GlobeNewsWire • 05/04/23